ImmuneOnco Biopharmaceuticals (Shanghai) Inc
Company Profile
Business description
ImmuneOnco Biopharmaceuticals (Shanghai) Inc is a science-driven biotechnology company dedicated to the development of immuno-oncology therapies. It is one of the few biotechnology companies globally adopting a systematic approach to harness both the innate and adaptive immune systems. It has developed a rich pipeline of 14 drug candidates with eight ongoing clinical programs, featured by a comprehensive innate-immunity-based asset portfolio. Its pipeline reflects its extensive understanding of the frontiers of cancer biology and immunology and its expertise in turning scientific research into drug candidates.
Contact
1000 Zhangheng Road
Unit 15, China (Shanghai) Pilot Free Trade Zone
Pudong New Area
Shanghai
CHNT: +86 2138016387
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
195
Stocks News & Analysis
stocks
Cutting our fair value on ASX share after poor guidance
stocks
2 companies poised to capitalize on the rise of GLP-1 drugs
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,890.30 | 11.00 | -0.12% |
| CAC 40 | 8,052.51 | 55.92 | -0.69% |
| DAX 40 | 24,162.65 | 116.64 | 0.49% |
| Dow JONES (US) | 47,560.29 | 179.03 | -0.38% |
| FTSE 100 | 9,642.01 | 3.08 | -0.03% |
| HKSE | 25,434.23 | 331.13 | -1.29% |
| NASDAQ | 23,576.49 | 30.58 | 0.13% |
| Nikkei 225 | 50,655.10 | 73.16 | 0.14% |
| NZX 50 Index | 13,422.44 | 32.34 | -0.24% |
| S&P 500 | 6,840.51 | 6.00 | -0.09% |
| S&P/ASX 200 | 8,600.80 | 10.30 | -0.12% |
| SSE Composite Index | 3,909.52 | 14.56 | -0.37% |